Novavax Q4 revenues up 93% on Gates Foundation grant

|By:, SA News Editor

Novavax (NASDAQ:NVAX) Q4 results ($M): Revenue: 10.4 (+92.6%); net loss: (50.8) (+11.0%); loss/share: (0.16) (+23.8%).

Key milestones for 2018/2019:

Phase 2 study of quadrivalent NanoFlu vaccine to launch in Q3.

4,600 participants in Phase 3 Prepare study of RSV F vaccine to be reached in Q2. Interim efficacy data in Q1 2019.

Subscribe for full text news in your inbox